Prothena presents pipeline update highlighting two partnered Phase 3 programs
PRTA•Prothena achieved a $50 million Phase 3 enrollment milestone for partnered ATTR cardiomyopathy treatment coramitug. Remaining potential milestones exceed $2.25 billion across three partnered programs.
1. Partnered programs
Prothena said it achieved a $50 million Phase 3 enrollment milestone for coramitug, its partnered ATTR cardiomyopathy treatment. Remaining potential milestones across three partnered programs exceed $2.25 billion, with sales royalties also available from prasinezumab and moponetug.
2. Trial timelines
Phase 3 trials of prasinezumab for Parkinson's disease and coramitug for ATTR cardiomyopathy are expected to finish in 2029. Moponetug Phase 2 TargetTau-1 data in Alzheimer's disease are expected in the first half of 2027.
3. Research investment
Prothena said its research investment focuses on preclinical CYTOPE technology and PRX012-TfR, while it explores additional collaborations and licensing deals for unpartnered programs.
